"Gene Therapy Utilizing Enzymes Capable of Extracellular Prodrug Conversion as Well as Conversion of Multiple Prodrugs."

According to an abstract submitted by the authors to the 88th Annual Meeting of the American Association for Cancer Research, held April 12-16, 1997, in San Diego, California, "A promising new therapy for cancer is gene-directed enzyme prodrug therapy (GDEPT) where genes which code for a prodrug-activating enzyme are delivered to a tumor, followed by delivery of a nontoxic prodrug. The genes used most frequently in gene therapy trials to date code for the enzymes cytosine deaminase or HSV thymidine kinase. Both of these enzymes are intracellular enzymes which activate a single prodrug. We have developed three potentially improved genes for use in gene therapy. We have manipulated the...

Want to see the full article?

• Purchase this article for only $3.00